Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

579002

Sigma-Aldrich

(Z)-4-Hydroxytamoxifen

≥99% (HPLC), solid, estrogen receptor modulator, Calbiochem

Synonym(s):

Tamoxifen, 4-Hydroxy-, (Z)-, (Z)-4-Hydroxytamoxifen, 4-OH-TAM, Estrogen Receptor Signaling Regulator II

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C26H29NO2
CAS Number:
68047-06-3
Molecular Weight:
387.51
MDL number:
MFCD00278780
UNSPSC Code:
12352200
NACRES:
NA.77

product name

Tamoxifen, 4-Hydroxy-, (Z)-, A cell-permeable, active metabolite of Tamoxifen that acts as a potent inhibitor of PKC. It is more potent than the parent compound and inhibits PKC by modifying its catalytic domain.

Quality Level

200

Assay

≥99% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

color

white

solubility

methanol: 10 mg/mL
ethanol: 20 mg/mL (heating may be required)

shipped in

ambient

storage temp.

2-8°C

InChI

1S/C26H29NO2/c1-4-25(20-10-14-23(28)15-11-20)26(21-8-6-5-7-9-21)22-12-16-24(17-13-22)29-19-18-27(2)3/h5-17,28H,4,18-19H2,1-3H3/b26-25-

InChI key

DODQJNMQWMSYGS-QPLCGJKRSA-N

General description

A cell-permeable, active metabolite of Tamoxifen (Cat. No. 579000) that acts as a potent inhibitor of PKC. It is more potent than the parent compound and inhibits PKC by modifying its catalytic domain. Also available as a 10 mM solution in EtOH (Cat. No. 508225).
A cell-permeable, active metabolite of Tamoxifen (Cat. No. 579000) that acts as a potent inhibitor of PKC. It is more potent than the parent compound and inhibits PKC by modifying its catalytic domain.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
PKC
Product does not compete with ATP.
Reversible: no

Warning

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Gundimeda, U., et al. 1996. J. Biol. Chem. 271, 13504.
Ye, Q. and Bodell, W.J. 1996. Carcinogenesis 17, 1747.
Laser, R., et al. 1985. Eur. J. Cancer Clin. Oncol. 21, 985.
Jordan, V.C., et al. 1978. J. Toxicol. Environ. Health 4, 364.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Statements

H302,H350,H360FD,H410

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1B - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kusmardi Kusmardi et al.
F1000Research, 10, 902-902 (2021-10-26)
Background: Research in natural substances for their anticancer potential has become increasingly popular. Lunasin, a soybean protein, is known to inhibit cancer progression via various pathways.  The aim of this study was to investigate the effect of Lunasin Extract (LE)
Shangyue Zhang et al.
Redox biology, 71, 103124-103124 (2024-03-20)
Cardiomyocyte senescence is an important contributor to cardiovascular diseases and can be induced by stressors including DNA damage, oxidative stress, mitochondrial dysfunction, epigenetic regulation, etc. However, the underlying mechanisms for the development of cardiomyocyte senescence remain largely unknown. Sulfur dioxide
Salli Antila et al.
Nature cardiovascular research, 3, 474-491 (2024-08-01)
Discovery of meningeal lymphatic vessels (LVs) in the dura mater, also known as dural LVs (dLVs) that depend on vascular endothelial growth factor C expression, has raised interest in their possible involvement in Alzheimer's disease (AD). Here we find that
Daniel R Schmidt et al.
Communications medicine, 3(1), 108-108 (2023-08-10)
Genetically engineered mouse models (GEMMs) of cancer are powerful tools to study mechanisms of disease progression and therapy response, yet little is known about how these models respond to multimodality therapy used in patients. Radiation therapy (RT) is frequently used
Si Chen et al.
Molecular carcinogenesis, 62(2), 249-260 (2022-11-03)
Breast cancer is the most common cancer in women worldwide. Although tamoxifen (TAM), a selective estrogen receptor (ER) modulator, is widely used to treat ER-positive breast cancers, resistance to TAM remains a major clinical problem. NADPH-dependent cytochrome P450 reductase (POR) is
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service